title: Arterial chemoradiotherapy for carcinomas of the external auditory canal and middle ear.
abstract: OBJECTIVE
  The purpose of this study was to estimate the efficacy of superselective arterial chemoradiotherapy for locally advanced carcinomas of the external auditory canal and middle ear.
  
  
  METHODS
  A retrospective study of clinical data for consecutive patients with locally advanced carcinomas of the external auditory canal and middle ear.
  
  
  METHODS
  Thirteen patients with locally advanced carcinomas of the external auditory canal and middle ear (T3: one patient, T4: 12 patients) were reviewed. The median follow-up duration in the living patients was 33 months. The total dose of radiation therapy was 60 Gy using conventional fractionation. Four, five, or six courses of a superselective arterial infusion (cisplatin 50 mg) were given weekly.
  
  
  RESULTS
  The overall survival and progression-free survival rates at 2 years, calculated by the Kaplan-Meier method, were 58.7% and 53.8%, respectively. No late-phase adverse effects due to chemoradiation and no adverse effects due to catheterization were observed.
  
  
  CONCLUSIONS
  These results suggest that superselective arterial chemoradiation can be a treatment option for locally advanced carcinomas of the external auditory canal and middle ear.
authors.affiliation: Department of Radiology, Hyogo College of Medicine, Hyogo, Japan; Department of Radiation Oncology, Meiwa Cancer Clinic, Hyogo, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Fujiwara
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Doi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Takada
authors.forename: Soichi
authors.initials: S
authors.lastname: Odawara
authors.forename: Yasue
authors.initials: Y
authors.lastname: Niwa
authors.forename: Reiichi
authors.initials: R
authors.lastname: Ishikura
authors.forename: Norihiko
authors.initials: N
authors.lastname: Kamikonya
authors.forename: Tomonori
authors.initials: T
authors.lastname: Terada
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Uwa
authors.forename: Kosuke
authors.initials: K
authors.lastname: Sagawa
authors.forename: Shozo
authors.initials: S
authors.lastname: Hirota
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000628:therapy*; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D004424:Ear Canal; D004428:Ear Neoplasms / Q000401:mortality / Q000628:therapy*; D004432:Ear, Middle; D004621:Embolization, Therapeutic / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
keywords: Arterial chemotherapy; carcinomas of the external auditory canal and middle ear; radiation therapy